Uncategorized

Regorafenib as monotherapy has demonstrated an overall survival benefit versus placebo in the pivotal Phase III CORRECT study and has shown activity irrespective of micro-satellite status in a retrospective analysis from this study, though with limited responses observed. Despite progress in the treatment of CRC, including the advance of effective immuno-oncology Read more…

Medicaid beneficiaries—particularly those from diverse communities that have been historically marginalized—have long been under-represented in clinical trials due to factors such as participation costs, time away from work, and travel expenses. Beginning January 2022, CMS will be required under the Clinical Treatment Act—part of the $2.3 trillion omnibus spending and relief Read more…

A federal court judge dismissed all claims against dozens of generic manufacturers and retailers in sprawling litigation over allegations that the Zantac heartburn pill may contain a carcinogen, although brand-name drug makers will continue to face more than 1,400 lawsuits over the issue. The ruling is the latest chapter in Read more…

Many newly approved cancer drugs fail to clearly communicate survival benefits associated with their use on the label, according to an analysis published Monday by JAMA Internal Medicine. Of the 125 drugs designed to treat cancer approved by the U.S. Food and Drug Administration between 2014 and 2018, 22 included evidence on their Read more…

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in combination with pomalidomide and dexamethasone (Pd) for the treatment of adult patients with multiple myeloma who have received at least one prior line of therapy, including lenalidomide Read more…

In 2019, the FDA granted accelerated approval for PADCEV for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1/L1 inhibitor and a platinum-containing chemotherapy before (neoadjuvant) or after (adjuvant) surgery, or in a locally advanced or metastatic urothelial cancer setting. The Read more…

A recent study found that Black patients with ovarian cancer continue to have worse survival outcomes, but the data suggests that adherence to treatment guidelines may not be the cause. This research was presented during the ASCO 2021 Annual Meeting (Abstract 5552).​ “Racial disparities exist in outcomes for many cancers, Read more…

In the first head-to-head trial of BTKs in chronic lymphocytic leukemia, acalabrutinib demonstrated non-inferior progression-free survival with less cardiotoxicity and fewer discontinuations due to adverse events when compared to ibrutinib, according to findings presented at the ASCO 2021 Virtual Annual Meeting (Abstract 7500). “Chronic lymphocytic leukemia, for a long time, Read more…

Approximately 10 percent of cancer cases worldwide are thought to be caused by viruses. Viruses can be roughly divided into two types—those that have DNA as their genetic material and those that have RNA. The effects of both types of viruses on cancer development are highly complicated. Both have been Read more…

Back when people first heard about Pfizer-BioNTech and Moderna’s COVID-19 vaccines, the mRNA technology behind them sounded like the stuff of science fiction. But while the mRNA approach seems revolutionary, long before anyone had heard of COVID-19, researchers had been developing mRNA vaccines to fight cancer, autoimmune diseases such as multiple Read more…